Trametinib

Generic Name: Trametinib

Brand Names: Mekinist, Spexotras

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₃FIN_₅O_₄

CAS Number: 871700-17-3

Unique Ingredient Identifier: 33E86K87QN

Background: Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...

Indication: Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

It is used in combination with dabrafenib for the:
...

Associated Conditions: Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors

Associated Therapies: -

Clinical Trials

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Phase 1

Withdrawn

Conditions: Melanoma

Interventions: Drug: trametinib
Drug: nab-paclitaxel

First Posted Date: 2014-11-25

Last Posted Date: 2019-05-30

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT02300935

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Florida Cancer Center, Sarasota, Florida, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions: Drug: trametinib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2014-11-20

Last Posted Date: 2021-05-28

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 9

Registration Number: NCT02296112

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

Phase 1

Completed

Conditions: Hepatocellular Cancer
Liver Cancer

Interventions: Drug: Trametinib
Drug: Sorafenib

First Posted Date: 2014-11-17

Last Posted Date: 2021-06-10

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 17

Registration Number: NCT02292173

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Phase 1

Terminated

Conditions: Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

Interventions: Drug: Momelotinib (MMB)
Drug: Trametinib

First Posted Date: 2014-10-07

Last Posted Date: 2019-02-01

Lead Sponsor: Sierra Oncology LLC - a GSK company

Target Recruit Count: 21

Registration Number: NCT02258607

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Phase 2

Active, not recruiting

Conditions: Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7

Interventions: Drug: Dabrafenib
Other: Laboratory Biomarker Analysis
Procedure: Therapeutic Conventional Surgery
Drug: Trametinib

First Posted Date: 2014-09-04

Last Posted Date: 2024-07-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT02231775

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Lapatinib Plus Trametinib in KRAS Mutant NSCLC

Phase 1

Conditions: Colorectal Cancer

Interventions: Drug: Lapatinib
Drug: trametinib

First Posted Date: 2014-09-03

Last Posted Date: 2018-08-31

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02230553

Locations: 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Thyroid Gland Carcinoma
Poorly Differentiated Thyroid Gland Carcinoma
Recurrent Thyroid Gland Carcinoma
Refractory Thyroid Gland Carcinoma
Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
Stage IV Thyroid Gland Papillary Carcinoma AJCC v7
Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7
Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7
Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7
Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7

Interventions: Procedure: Computed Tomography
Other: Iodine I 124
Radiation: Iodine I-131
Other: Laboratory Biomarker Analysis
Other: Pharmacodynamic Study
Procedure: Positron Emission Tomography
Drug: Trametinib

First Posted Date: 2014-06-02

Last Posted Date: 2024-07-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT02152995

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Phase 1

Withdrawn

Conditions: Melanoma

Interventions: Drug: Dabrafenib
Drug: Trametinib
Drug: Metformin

First Posted Date: 2014-05-20

Last Posted Date: 2023-11-18

Lead Sponsor: University of Louisville

Registration Number: NCT02143050

Locations: 🇺🇸
James Graham Brown Cancer Center-Universityof Louisville, Louisville, Kentucky, United States
🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States